This study will evaluate the changes in sexual function, reproductive function and mental health of male patients discharged from the hospital with COVID-19, and the impact of SARS-CoV-2 on male reproductive health and mental health compared with healthy people during the same period. In addition, men's semen examination reports before and after the new coronavirus pneumonia event will be collected and compared to assess the impact of the event on the quality of men's semen. Also, This study will test the SARS-CoV-2 nucleic acid of the urogenital system of male patients discharged with COVID-19 to provide evidence for the effect of the new coronavirus on the male reproductive system.
This study will test SARS-CoV-2 nucleic acids in urine, prostate fluid, and semen of
participants with COVID-19 at the first follow-up. All participants will be followed up for 1
year. During follow-up, International Index of Erectile Function-5 (IIEF-5), Quality
Evaluation Questionnaire (QEQ), symptom list chart-90 (SCL-90) questionnaire evaluation and
sexual function related examinations (including nocturnal penile tumescence, color duplex
ultrasonography, etc. ) and fertility-related examinations (including sex hormones, semen
routine examinations, etc.) will be performed to assess the changes in male sexual function,
reproductive function and mental health of male patients discharged with COVID-19, and the
impact of SARS-CoV-2 on male reproductive and mental health. In addition, collect male semen
examination reports from April to December in 2017-2020 to evaluate the impact of new
coronavirus pneumonia incidents on male semen quality.
Other: Coronavirus Disease 2019
male patients who have developed COVID-19
Inclusion Criteria:
1. Age≥ 18, ≤ 60 years old;
2. Have a fixed sex partner and regular sex life;
3. No previous infectious diseases, chronic diseases, tumor history, and male sexual
function and fertility diseases;
4. Normal erectile function, IIEF-5 score> 21 points;
5. Have complete clinical information and contact information；
6. Understand and sign the informed consent form.
Exclusion Criteria:
1. Hypertension, diabetes, coronary heart disease, hyperlipidemia and other chronic
diseases；
2. Past history of endocrine diseases such as hypopituitarism, hypogonadism, abnormal
thyroid function, etc;
3. Past history of mumps virus infection;
4. Past history of bladder cancer, prostate cancer, brain spine injury, testicular
injury, pelvic fracture, urethral injury and history of surgical treatment;
5. Severe cardiovascular and cerebrovascular diseases, severe lung diseases, severe
hepatitis;
6. Past psychological or mental illness;
7. Contact information not available.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Investigator: Tao Wang, M.D
tjhwt@126.com
Investigator: Jihong Liu
Tao Wang, M.D
027-83663640
tjhwt@126.com
Jihong Liu, M.D, Principal Investigator
Departments of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China